Skip to Content
Palsonify Logo

Now FDA Approved

Palsonify Logo

Now FDA Approved

GO TO PALSONIFY.COM

News & Events

Show:

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics grants non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an...

READ MORE

Webcast: Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results

Event Date: Crinetics company management will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.

READ MORE

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

SAN DIEGO – October 6, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter...

READ MORE

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults

Crinetics announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with...

READ MORE

FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Event Date: Crinetics will host an investor conference call on September 25, at 6:00 pm Eastern Time to discuss the FDA approval of PALSONIFY. Live & Archived Webcast: https://events.q4inc.com/attendee/443074040 Dial-in Details: Domestic: 1-833-470-1428International: 1-646-844-6383Conference ID: 120796

READ MORE

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics grants non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an...

READ MORE

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor...

READ MORE

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an...

READ MORE

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.

READ MORE